Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
- PMID: 26553517
- DOI: 10.1038/nrneph.2015.173
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Abstract
Chronic kidney disease (CKD) is a common comorbidity in patients with type 2 diabetes mellitus (T2DM) and both conditions are increasing in prevalence. CKD is estimated to affect ∼50% patients with T2DM globally, and its presence and severity markedly influences disease prognosis. CKD is more common in certain patient populations, including the elderly, those with youth-onset diabetes mellitus, those who are obese, certain ethnic groups, and disadvantaged populations. These same settings have also seen the greatest increase in the prevalence of T2DM, as exemplified by the increasing prevalence of T2DM in low-to- middle income countries. Patients from low-to-middle income countries are often the least able to deal with the burden of T2DM and CKD and the health-care facilities of these countries least able to deal with the demand for equitable access to renal replacement therapies. The increasing prevalence of younger individuals with T2DM, in whom an accelerated course of complications can be observed, further adds to the global burden of CKD. Paradoxically, improvements in cardiovascular survival in patients with T2DM have contributed to patients surviving longer, allowing sufficient time to develop renal impairment. This Review explores how the changing epidemiology of T2DM has influenced the prevalence and incidence of associated CKD across different populations and clinical settings.
Similar articles
-
Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.Am J Kidney Dis. 2019 Jan;73(1):72-81. doi: 10.1053/j.ajkd.2018.06.017. Epub 2018 Sep 1. Am J Kidney Dis. 2019. PMID: 30177484 Free PMC article.
-
Chronic Kidney Disease-Epidemiology Collaboration (CKD - EPI) classification of kidney function and predictors of kidney dysfunction among type 2 diabetes mellitus patients in a tertiary hospital in Ghana.Pan Afr Med J. 2024 Dec 20;49:132. doi: 10.11604/pamj.2024.49.132.43686. eCollection 2024. Pan Afr Med J. 2024. PMID: 40190429 Free PMC article.
-
High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care.Prim Care Diabetes. 2015 Feb;9(1):31-8. doi: 10.1016/j.pcd.2014.06.001. Epub 2014 Jul 21. Prim Care Diabetes. 2015. PMID: 25066820
-
[Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease].Nefrologia. 2014;34(1):34-45. Nefrologia. 2014. PMID: 24611186 Spanish.
-
Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease.Hormones (Athens). 2013 Oct-Dec;12(4):483-94. doi: 10.14310/horm.2002.1436. Hormones (Athens). 2013. PMID: 24457396 Review.
Cited by
-
Accelerated Kidney Aging in Diabetes Mellitus.Oxid Med Cell Longev. 2020 Jul 27;2020:1234059. doi: 10.1155/2020/1234059. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32774664 Free PMC article. Review.
-
Does a Ketogenic Diet Have a Place Within Diabetes Clinical Practice? Review of Current Evidence and Controversies.Diabetes Ther. 2024 Jan;15(1):77-97. doi: 10.1007/s13300-023-01492-4. Epub 2023 Nov 15. Diabetes Ther. 2024. PMID: 37966583 Free PMC article. Review.
-
Methylenetetrahydrofolate reductase genetic polymorphism and the risk of diabetic nephropathy in type 2 diabetic patients.Medicine (Baltimore). 2020 Aug 28;99(35):e21558. doi: 10.1097/MD.0000000000021558. Medicine (Baltimore). 2020. PMID: 32871871 Free PMC article.
-
The Effects of Mental Stress on Non-insulin-dependent Diabetes: Determining the Relationship Between Catecholamine and Adrenergic Signals from Stress, Anxiety, and Depression on the Physiological Changes in the Pancreatic Hormone Secretion.Cureus. 2019 Aug 24;11(8):e5474. doi: 10.7759/cureus.5474. Cureus. 2019. PMID: 31485387 Free PMC article. Review.
-
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.Front Endocrinol (Lausanne). 2023 Jan 30;14:1111984. doi: 10.3389/fendo.2023.1111984. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36793276 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical